Tyk2作为人病毒/细菌性肺炎免疫调节靶点
本研究建立人肺离体共感染模型,探讨流感A病毒(IAV)继发肺炎链球菌肺炎的先天免疫机制。发现I型和III型干扰素抑制肺炎链球菌诱导的IL-1β释放,进而抑制GM-CSF产生;抑制Tyk2可完全恢复IL-1β-GM-CSF轴并减少细菌生长。药理学抑制Tyk2可能成为维持内源性GM-CSF水平的新治疗选择。
要点
- I型和III型IFN抑制肺炎链球菌诱导的IL-1β和GM-CSF释放
- 抑制Tyk2可恢复IL-1β-GM-CSF轴并减少细菌生长
- Tyk2抑制或为IAV继发细菌性肺炎的潜在治疗策略
核心结论
- 药理学抑制Tyk2可能维持IAV相关继发性细菌性肺炎中有益的内源性GM-CSF水平。
研究设计与样本
- 建立人肺离体共感染模型研究IAV继发肺炎链球菌肺炎的先天免疫机制。
主要发现
- I型和III型干扰素抑制肺炎链球菌诱导的IL-1β释放。
- IL-1β缺乏导致细菌诱导的GM-CSF释放受抑。
- 特异性抑制IFN受体I和III相关的Tyk2完全恢复IL-1β-GM-CSF轴并减少细菌生长。
- 先前IAV感染通过I型和III型IFN依赖性途径阻断早期IL-1β和GM-CSF。
临床怎么用
- Tyk2抑制可能作为IAV继发细菌性肺炎的治疗选项,以维持GM-CSF水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The severity and lethality of influenza A virus (IAV) infections is frequently aggravated by secondary bacterial pneumonia. However, the mechanisms in human lung tissue that provoke this increase in fatality are unknown and therapeutic immune modulatory options are lacking.We established a human lung ex vivo co-infection model to investigate innate immune related mechanisms contributing to the susceptibility of secondary pneumococcal pneumonia.We revealed that type I and III interferon (IFN) inhibits Streptococcus pneumoniae-induced interleukin (IL)-1β release. The lack of IL-1β resulted in the repression of bacterially induced granulocyte-macrophage colony-stimulating factor (GM-CSF) liberation. Specific inhibition of IFN receptor I and III-associated tyrosine kinase 2 (Tyk2) completely restored the S. pneumoniae-induced IL-1β-GM-CSF axis, leading to a reduction of bacterial growth. A preceding IAV infection of the human alveolus leads to a type I and III IFN-dependent blockade of the early cytokines IL-1β and GM-CSF, which are key for orchestrating an adequate innate immune response against bacteria. Their virally induced suppression may result in impaired bacterial clearance and alveolar repair.Pharmacological inhibition of Tyk2 might be a new treatment option to sustain beneficial endogenous GM-CSF levels in IAV-associated secondary bacterial pneumonia.
引用
- Berg J, Zscheppang K, Fatykhova D, et al. Tyk2 as a target for immune regulation in human viral/bacterial pneumonia. Eur Respir J. 2017. PMID: 28705941. doi:10.1183/13993003.01953-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。